GFAP and congenital rubella syndrome: Consistent with results from the LPS model, treatments with D4 induced significant reductions in the number of GFAP+ astrocytes (Control/vehicle, 100.0 ± 23.0%; CRS/vehicle, 418.6 ± 62.0%; CRS/D4, 199.7 ± 48.8%), as well as a decrease in the CBF uptake in GFAP+ astrocytes (Control/vehicle, 100.0 ± 39.0%; CRS/vehicle, 444.5 ± 81.7%; CRS/D4, 267.6 ± 38.8) in the hippocampal DG (Fig. 5A–C).